NRX Pharmaceuticals Inc. (NASDAQ: NRXP)
$3.3500
+0.6600 ( +14.73% ) 2.3M
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Market Data
Open
$3.3500
Previous close
$2.6900
Volume
2.3M
Market cap
$33.50M
Day range
$2.6650 - $3.4350
52 week range
$1.1000 - $7.3330
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Aug 20, 2024 |
8-k | 8K-related | 20 | Aug 15, 2024 |
8-k | 8K-related | 25 | Aug 14, 2024 |
10-q | Quarterly Reports | 71 | Aug 14, 2024 |
8-k | 8K-related | 14 | Aug 12, 2024 |
8-k | 8K-related | 14 | Jun 27, 2024 |
3 | Insider transactions | 1 | Jun 26, 2024 |
8-k | 8K-related | 15 | Jun 20, 2024 |
8-k | 8K-related | 15 | May 23, 2024 |
8-k | 8K-related | 17 | May 16, 2024 |